ClinVar Miner

Submissions for variant NM_025114.4(CEP290):c.2T>A (p.Met1Lys)

gnomAD frequency: 0.00001  dbSNP: rs368984997
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV001091344 SCV001247312 pathogenic not provided 2018-08-01 criteria provided, single submitter clinical testing
Invitae RCV001862693 SCV002201732 pathogenic Familial aplasia of the vermis; Meckel-Gruber syndrome; Nephronophthisis 2024-01-11 criteria provided, single submitter clinical testing This sequence change affects the initiator methionine of the CEP290 mRNA. The next in-frame methionine is located at codon 11. This variant is present in population databases (rs368984997, gnomAD 0.0009%). Disruption of the initiator codon has been observed in individuals with Leber congenital amaurosis and/or Senior-Loken syndrome (PMID: 17345604, 21866095). ClinVar contains an entry for this variant (Variation ID: 871409). This variant disrupts the p.Trp7 amino acid residue in CEP290. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16682970, 27422788). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV002482162 SCV002785969 likely pathogenic Leber congenital amaurosis 10; Meckel syndrome, type 4; Senior-Loken syndrome 6; Joubert syndrome 5; Bardet-Biedl syndrome 14 2022-04-23 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV004536141 SCV004713632 pathogenic CEP290-related disorder 2023-10-27 criteria provided, single submitter clinical testing The CEP290 c.2T>A variant is predicted to disrupt the translation initiation site (Start Loss). This variant was reported in individuals with Leber congenital amaurosis (Patient 416 in Perrault et al. 2007. PubMed ID: 17345604; Supplemental Table 1 in Weisschuh et al. 2020. PubMed ID: 32531858; Table S2 in Drivas et al. 2015. PubMed ID: 26062849) and in a patient with renal and ophthalmic features (Patient 63 in Best et al. 2022. PubMed ID: 35764379). This variant is reported in 0.0016% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/12-88535083-A-T) and has been interpreted as likely pathogenic and pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/871409/). Of note, a different variant that disrupts the methionine start codon (c.1A>G) has also been reported in patients with CEP290-related disorders (Patient F57 in Helou. 2007. PubMed ID: 17617513). Based on this evidence, we interpret the c.2T>A (start loss) variant as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.